Immunogenicity of synthetic conjugates of Lewis(y) oligosaccharide with proteins in mice: Towards the design of anticancer vaccines

Cancer Immunology Immunotherapy

Volumn 45, Issue 6, 1998, Pages 281-286

  Kudryashov, Valery ^a   Kim, Hyunjin M ^b   Ragupathi, Govindaswami ^a   Danishefsky, Samuel J ^a   Livingston, Philip O ^a   Lloyd, Kenneth O ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Antitumor vaccine; Immunogenicity; Lewis(y) antigen; Oligosaccharide

Indexed keywords

CANCER ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOLOGICAL ADJUVANT; KEYHOLE LIMPET HEMOCYANIN; OLIGOSACCHARIDE; QS 21;

ANTIBODY RESPONSE; ARTICLE; BLOOD GROUP LEWIS SYSTEM; CANCER IMMUNIZATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONJUGATE; CROSS REACTION; HUMAN; HUMAN CELL; IMMUNE ADHERENCE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOREACTIVITY; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR IMMUNOLOGY;

ANIMALS; CANCER VACCINES; CARBOHYDRATE SEQUENCE; FEMALE; GLYCOCONJUGATES; HEMOCYANIN; HUMANS; LEWIS BLOOD-GROUP SYSTEM; MICE; MICE, INBRED BALB C; SERUM ALBUMIN, BOVINE;

EID: 0031934948     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050444     Document Type: Article

References (36)

1. Avery OT, Goebel WF (1931) Chemoimmunological studies on conjugated carbohydrate-proteins. V. The immunological specificity of an antigen prepared by combining the cupsular polysaccharide of type III pneumococcus with foreign protein. J Exp Med 54:437
2. Bilodeau MT, Park TK, Hu S, Randolph JT, Danishefsky SJ, Livingston PO, Zhang S (1995) Total synthesis of a human breast tumor associated antigen. J Am Chem Soc 117:7840
3. Danishefsky SJ, Bilodeau MT (1996) Glycals in organic synthesis: the evolution of comprehensive strategies for the assembly of oligosaccharides and glycoconjugates of biological consequence. Angew Chem Int Ed Engl 35:1380
4. b blood group determinants and of H-type I and H-type II oligosaccharides. J Am Chem Soc 117:5701
5. Dippold WG, Lloyd KO, Li LTC, Ikeda H, Oettgen HF, Old LJ (1980) Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies. Proc Natl Acad Sci USA 77:6114
6. Feizi T (1985) Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are onco-developmental antigens. Nature 314:53
7. Hakomori S-I (1996) Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res 56:5309
8. Hardy MR, Townsend RR, Lee YC (1988) Monosaccharide analysis of glycoconjugates by anion exchange chromatography with pulsed amperometric detection. Anal Biochem 170:54
9. D3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines. Cancer Res 54:197
10. Helling F, Zhang S, Shang A, Adluri S, Calves M, Koganty R, Longenecker BM, Yao T-J, Oettgen HF, Livingston PO (1995) GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 55:2783
11. Y blood group-related antigens in human malignant, premalignant, and nonmalignant colonic tissues. Cancer Res 46:5985
12. y determinants. Proc Natl Acad Sci USA 91:12957
13. Landsteiner K (1936) Specificity of serological reactions. Thomas, Springfield, Ill
14. y are preferentially expressed on small-cell lung cancer cells as detected by the monoclonal antibody MLuC1. Int J Cancer 51:225
15. Livingston PO (1992) Construction of cancer vaccines with carbohydrate and protein (peptide) tumor antigens. Curr Opin Immunol 4:624
16. Livingston PO, Natoli EJ, Calves MJ, Stockert E, Oettgen HF, Old LJ (1987) Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci USA 84:2911
17. Livingston PO, Koganty RR, Longenecker BM, Lloyd KO, Calves MJ (1991) Studies on the immunogenicity of synthetic and natural Thomsen-Friedenreich (TF) antigens in mice: augmentation of the response by Quil A and SAF-m adjuvants and analysis of the specificity of the responses. Vaccine Res 1:99
18. Livingston PO, Adluri S, Helling F, Yao T-J, Kensil CR, Newman MJ, Marciani D (1994) Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine 12:1275
19. Lloyd KO (1990) Molecular characteristics of tumor antigens. Immunol Allergy Clin N America 10:765
20. Lloyd KO, Savage A (1991) High performance anion exchange (HPAE) chromatography of reduced oligosacchardies from sialomucins. Glycoconj J 8:493
21. Lloyd KO, Kabat EA, Layug EJ, Gruezo E (1966) Immunochemical studies on blood groups. XXXIV. Structures of some oligosaccharides produced by alkaline degradation of blood group A, B, and H substances. Biochemistry 5:1489
22. Longenecker BM, MacLean G (1993) Prospects for mucin epitopes in cancer vaccines. Immunologist 1:89
23. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265
24. MacLean GD, Reddish M, Koganty RR, Wong T, Gandhi S, Smolenski M, Samuel J, Nabholtz JM, Longenecker BM (1993) Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunol Immunother 36:215
25. Ragupathi G (1996) Carbohydrate antigens as targets for active specific immunotherapy. Cancer Immunol Immunother 43:152
26. Ragupathi G, Koganty RR, Qiu D, Lloyd KO, Livingston PO (1997) A novel and efficient method for synthetic carbohydrate conjugate vaccine preparation: synthesis of sialyl Tn-KLH conjugate using an 4-(4-N-maleimidomethyl)cyclohexane-1-carboxyl hydrazide (MMCCH) linker arm. Glycoconj J (in press)
27. Ragupathi G, Park TK, Zhang S, Kim IJ, Graber L, Adluri S, Lloyd KO, Danishefsky SJ, Livingston PO (1997) Immunization of mice with conjugates of fully synthetic hexasaccharide globo-H results in antibodies against human cancer cells: a combined chemical-immunological approach to the fashioning of an anticancer vaccine. Angew Chem Int Ed Engl 36:125
28. Real FX, Oettgen HF, Old LJ, Rose NR, Friedman H, Fahey JL (eds) (1986) Detection and analysis of antibodies against cancer cell surface antigens in the sera of cancer patients. Manual of clinical immunology, 3rd edn. American Society of Microbiology, Washington, DC, pp 798-802
29. D3 congeners (lactones, amide and gangliosidol) in patients with malignant melanoma. Int J Cancer 48:379
30. Sakamoto J, Yin BW, Lloyd KO (1984) Analysis of the expression of H, Lewis, X, Y and precursor blood group determinants in saliva and red cells using a panel of mouse monoclonal antibodies. Mol Immunol 21:1093
31. b, X, and Y blood group antigens in human colonic tumors and normal tissue and in human tumor-derived cell lines. Cancer Res 46:1553
32. Schneerson R, Robbins JB, Szu SC, Yang Y (1987) Vaccines composed of polysaccharide-protein conjugates: current status, unanswered questions, and prospects for the future. In: Bell R, Torrigiani G (eds) Towards better carbohydrate vaccines. Wiley, New York, pp 307
33. Schwartz BA, Gray GR (1977) Proteins containing reductively deaminated disaccharides. Synthesis and chemical characterization. Arch Biochem Biophys 181:542
34. Shiku H, Takahashi T, Oettgen HF, Old LJ (1976) Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new cell surface antigens. J Exp Med 144:873
35. Toyokuni T, Singhal AK (1995) Synthetic carbohydrate vaccines based on tumour-associated antigens. Chem Soc Rev 24:231
36. y) blood group antigen expression in epithelial ovarian cancer. Int J Cancer 65:406